TTNP: Bathi saben saham sajrone rolas wulan pungkasan Titan Pharmaceuticals Inc.

Logo korporat perusahaan titanpharm.com (TTNP)

Titan Pharmaceuticals relies on ProNeura technology for the treatment of Parkinson's disease and addictions, which serves as the primary growth catalyst. Niche protection is ensured by patents and stringent FDA requirements, while product output is managed through calibrated partner capacities. The trailing 12-month net income per share clearly demonstrates the effectiveness of this strategy, where -2.96 represents the current metric value.

Titan Pharma (TTNP) - Bathi saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 18.10.2025

Titan Pharma (TTNP) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis kabeh metrik perusahaan:TTNP - Titan Pharmaceuticals
Barang unggulan Titan Pharmaceuticals Inc.

The stability of Titan Pharmaceuticals (TTNP) is driven by the deep expertise of its scientists in developing implantable drug delivery systems. By analyzing the trailing twelve-month (TTM) EPS, an investor can see the net profit allocated per share over a year. The trend of this metric reflects the actual scalability of the business between quarterly reports. An upward trajectory confirms the effectiveness of development, while stagnation signals a limit to expansion. This trend determines the fair value of the asset.